NCT02323906终止1 期
A Phase 1b, Multi-Center, Open-Label, Dose Finding Study of CC-122 in Combination With Sorafenib in Subjects With Unresectable Hepatocellular Carcinoma
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 发起方
- Celgene
- 入组人数
- 12
- 试验地点
- 8
- 主要终点
- Adverse Event
研究概览
简要总结
CC-122-HCC-001 is a Phase 1b dose escalation and expansion clinical study of CC-122 in combination with sorafenib for subjects with unresectable HCC who have received no prior systemic therapy for HCC. The dose escalation phase of the study will explore several dose levels of CC-122 in combination with sorafenib, followed by an expansion part of the study using the optimal combination dose regimen.
详细描述
The primary objective of the study is to determine the safety and tolerability of CC-122 administered orally in combination with sorafenib, and to define the non-tolerated dose (NTD), the maximum tolerated dose (MTD), and the recommended phase 2 dose (RP2D).
The secondary objective of the study is to determine the preliminary efficacy of CC-122 in combination with sorafenib, based on response Evaluation Criteria in Solid Tumors (RECIST 1.1)
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject understands and voluntarily signs an informed consent document prior to conducting any study related assessments/procedures
- •Subject is 18 years of age or more at the time of signing the Informed Consent Form
- •Subject has a confirmed pathologic diagnosis of Hepatocellular carcinoma according to the American Association for the Study of Liver Diseases Guidelines.A biopsy performed at screening may serve as a diagnostic biopsy for subjects with radiographic diagnosis.
- •Subject has unresectable stage B (intermediate), or C (advanced) Hepatocellular carcinoma according to the Barcelona Clinic Liver Cancer staging.Stage B subjects must have progressed after, or are not eligible for curative resection, transplantation, embolic, or ablative therapies
- •Subject has at least one measurable lesion according to Response Evaluation Criteria in Solid Tumors version 1.
- •Evaluable target lesions may not have been treated with local therapy; previously treated lesions may only be evaluated as target lesions if they are the only lesions available and have shown objective definite progression after prior treatment. Local therapy must have been completed at least four weeks prior to baseline tumor evaluation
- •Satisfactory archival tumor biopsy tissue is retrieved, or new tumor biopsy is performed, prior to starting Cycle 1
- •Subject has life expectancy of more than 12 weeks
- •Subject has Eastern Cooperative Oncology Group Performance Status of 0 or 1
- •Subject has Child-Pugh score of less than 7 (ie, class A or better) with neither encephalopathy nor clinically significant ascites (ascites requiring paracentesis within 3 months of signing the ICF is excluded). Child-Pugh status is calculated based on clinical findings and laboratory results during the screening period.
- •Subject has the following laboratory parameters at screening:
- •Adequate hematologic function including:
- •Absolute Neutrophil Count of at least 1.5 x 109/L
- •Platelets of at least 75,000 x 106/L
- •Hemoglobin of at least 9 g/dL
- •International Normalized Ratio of at least 1.7
- •Adequate hepatic function including:
- •Serum aspartate aminotransferase and alanine amino-transferase of at least 5 times the upper limit of normal
- •Serum total bilirubin of at least 3 mg/dL
- •Serum albumin of at least 2.8 g/dL Note: Laboratories in combination must still be Child Pugh score less than 7
- •Other laboratory parameters:
- •Serum creatinine of at least 1.5 times the upper limit of normal
- •Potassium within normal range or corrected with supplements
- •For subjects with known or suspected cirrhosis, esophagogastroduodenoscopy ) within 12 months of signing the informed consent form, showing no evidence of untreated varices or stigmata of active bleeding (such as active ulcer, visible vessel, or blood) is required.
- •Subjects with history of upper GI bleeding must have an EGD of 3 months or less prior to signing the consent form confirming adequate prior endoscopic therapy (eg, no evidence of any untreated varices, recent or active bleeding, stigmata suggesting high risk for bleeding, active ulcer). Subjects with history/suspected esophageal varices must be on optimal medical management (eg, proton pump inhibitor and non-selective beta-blocker) per local institutional policy.
- •Subject is able to adhere to the study visit schedule and other protocol requirements
- •Pregnancy Prevention Risk Management Plan
- •Females of childbearing potential must undergo pregnancy testing based on the frequency outlined in Pregnancy Prevention Risk Minimization Plan and pregnancy results must be negative.
- •Unless practicing complete abstinence from heterosexual intercourse, sexually active FCBP must agree to use adequate contraceptive methods as specified in Pregnancy Prevention Risk Minimization Plan.
- •Complete abstinence is only acceptable in cases where this is the preferred and usual lifestyle of the subject.
- •Periodic abstinence (calendar ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable.
- •Males (including those who have had a vasectomy) must use barrier contraception (condoms) when engaging in sexual activity with Female of Childbearing Potential as specified in Pregnancy Prevention Risk Minimization Plan.
- •Males must agree not to donate semen or sperm for 3 months after last dose of CC-
- •All subjects must:
- •Understand that CC-122 could have a potential teratogenic risk.
- •Agree to abstain from donating blood while taking CC-122 or sorafenib and following discontinuation of their use.
- •Agree not to share either study drug with another person.
- •Other than the subject, Female of Childbearing Potential and males able to father a child should not handle CC-122 or touch the capsules, unless gloves are worn.
- •Be counseled about pregnancy precautions and risks of fetal exposure
排除标准
- •Subject has received previous systemic therapy for Hepatocellular carcinoma including sorafenib, chemotherapy and investigational agents
- •Subject has received any local anticancer therapy ≤ 4 weeks prior to baseline tumor evaluation
- •Subject has undergone major surgery within the last 4 weeks or minor surgery within the last 2 weeks prior to signing the Informed Consent Form or who have not recovered from surgery
- •Subject has received an investigational drug or therapy for disease other than Hepatocellular carcinoma within the last 4 weeks or 5 half-lives, whichever is shorter, prior to signing the Informed Consent Form
- •Subject has completed any radiation treatment less than 2 weeks prior to signing the Informed Consent Form
- •Subject has received the last dose of α-interferon, ribavirin, sofobuvir and/or other antiviral therapies for Hepatitis C Virus (HCV) less than 4 weeks prior to signing the Informed Consent Form
- •Subject has any clinically significant bleeding, including bleeding from esophageal/gastric varices within ≤ 3 months of signing the informed consent form, which required transfusion, surgical procedure or hospitalization. Esophageal varices should be treated according to local standard practice (eg, ligation or banding and procedure completed ≤ 3 months prior to signing the informed consent form). See Inclusion Criterion 10
- •Subjects requiring therapeutic anticoagulation with either warfarin or low molecular weight heparin. Low dose low molecular weight heparin for catheter maintenance are permitted
- •Subject has tumor invasion of stomach or duodenum
- •Subject has histologic proof of fibrolamellar carcinoma
- •Subjects with known symptomatic brain metastasis
- •Subject has persistent diarrhea due to a malabsorptive syndrome (such as celiac sprue or inflammatory bowel disease) malabsorption ≥ National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE, Version 4.03) Grade 2, despite medical management, or any other significant GI disorder that could affect the absorption of either study drug
- •Subject has history of concurrent second cancers requiring active, ongoing systemic treatment.
- •Subject has a known history of human immunodeficiency virus (HIV) seropositivity (HIV testing is not mandatory)
- •Subject has peripheral neuropathy of at least NCI CTCAE Grade 2
- •Subject has a history of persistent skin rash of at least NCI CTCAE Grade 2
- •Subject has impaired cardiac function or clinically significant cardiac disease including any of the following:
- •LVEF (left ventricular ejection fraction) of 45% or less as determined by MUGA (multi-gated acquisition) or ECHO (Echocardiogram)
- •Complete left bundle branch or bifascicular block
- •Congenital long QT syndrome
- •Persistent or clinically meaningful ventricular arrhythmias
- •QTcF greater than 460 msec on Screening ECG (mean of triplicate recordings)
- •Unstable angina pectoris or myocardial infarction less than 6 months prior to starting either study drug
- •Uncontrolled hypertension (blood pressure greater than 140/90 mmHg on at least 2 measurements on sequential visits, despite blood pressure medication)
- •Subjects with baseline blood pressure 140/90 mmHg are eligible but must have optimal medication for blood pressure management h. Troponin-T value more than the upper limit of normal or BNP greater than 100 pg/mL
- •Subject has acute or chronic active infectious disorders or uncontrolled nonmalignant illnesses whose control, in the opinion of the investigator, may be jeopardized by complications of this study therapy. Chronic hepatitis B and C virus (HBV and HCV) are excepted (ie, eligible for study); HBV requires antiviral therapy
- •Subject has undergone liver transplantation or other solid organ transplantation requiring immunosuppression
- •Subject is receiving chronic treatment with systemic corticosteroids or other potentially immunosuppressive agent. Intermittent topical or local injection of corticosteroids and oral/IV aldosterone or other mineralocorticoids is allowed
- •Subjects with history of non-healing wounds or ulcers, or bone fractures less than 3 months of a prior fracture
- •Subject is being treated with concomitant strong CYP3A4 inducers such as St. John's Wort, dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, phenobarbital. The use of concomitant strong CYP3A4 inducers may decrease sorafenib plasma concentrations and must be avoided.
- •Subject is a female who is pregnant or is breast feeding
- •Subject is unwilling or unable to comply with the protocol, in the opinion of the investigator
- •Subject has any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study
- •Subject has any condition that confounds the ability to interpret data from the study
研究组 & 干预措施
CC-122 + Fixed-dose Sorafenib
Experimental
A dose escalation and expansion clinical study of CC-122 in combination with sorafenib in subjects with unresectable HCC who have received no prior systemic therapy for HCC.
The dose escalation part of the study will explore several dose levels of CC-122 in combination with sorafenib, followed by an expansion part.
干预措施: CC-122 (Drug)
CC-122 + Fixed-dose Sorafenib
Experimental
A dose escalation and expansion clinical study of CC-122 in combination with sorafenib in subjects with unresectable HCC who have received no prior systemic therapy for HCC.
The dose escalation part of the study will explore several dose levels of CC-122 in combination with sorafenib, followed by an expansion part.
干预措施: Sorafenib (Drug)
结局指标
主要结局
Adverse Event
时间窗: Up to 3 years
Number of Participants with Adverse Events
Dose-Limiting Toxicity (DLT)
时间窗: 28 Days
Number of participants with a DLT. A DLT is defined as a treatment-related AE(s) occurring in Cycle 1 (including predose assessments on Cycle 2 Day 1).
次要结局
- Time to progression (TTP)(Up to 4 years)
- Disease control rate (DCR)(Up to 4 years)
- Overall Response Rate (ORR)(Up to 4 years)
- Duration of response (DoR)(Up to 4 years)
- Progression-free survival(Up to 4 years)
- Overall survival(Up to 4 years)
研究者
研究点 (8)
Loading locations...
相似试验
已完成
1 期
A Safety and Efficacy Study of CC-122 in Combination With Nivolumab in Subjects With Unresectable Hepatocellular Carcinoma (HCC)Carcinoma, HepatocellularNCT02859324Celgene21
已完成
1 期
A Phase 1b Open-label Study to Evaluate the Safety and Efficacy of CC-122 With Obinutuzumab (GA101) in Relapsed/Refractory DLBCL and iNHL.Lymphoma, Large B-Cell, DiffuseLymphoma, Non-HodgkinNCT02417285Celgene75
进行中（未招募）
1 期
Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat LymphomaLymphoma, B-CellNCT04884035Celgene224
进行中（未招募）
1 期
A Study of CC-99712, a BCMA Antibody-Drug Conjugate, in Participants With Relapsed and Refractory Multiple MyelomaMultiple MyelomaNCT04036461Celgene160
尚未招募
1 期
HY1272 in Patients With Locally Advanced or Metastatic Solid Tumors or Locally Advanced or Metastatic EGFRm+ NSCLCNSCLC Stage IVNCT06218940Newsoara Biopharma Co., Ltd.40